5°C

clear sky

TFL Updates
London Daily News

England considers capsule-sponge tests for reflux and Barrett’s monitoring

England considers capsule-sponge tests for reflux and Barrett’s monitoring

Two capsule-sponge tests could become an option for some people with persistent acid reflux and other risk factors for oesophageal cancer under draft guidance for the NHS in England.

The proposals would also allow the tests, Cytosponge and EndoSign, to be used in a structured monitoring programme for people already diagnosed with Barrett’s oesophagus, a condition in which cells in the lining of the food pipe have changed.

The National Institute for Health and Care Excellence (NICE) opened the recommendations for consultation on 16 November. They are not yet final, and a test would be an option for an eligible patient only where it is considered suitable. Some NHS services already use capsule-sponge testing; the proposal is not an announcement that it has been rolled out everywhere.

Who could be offered a test?

The proposed detection pathway covers people with persistent gastro-oesophageal reflux disease and multiple risk factors who do not need an urgent suspected-cancer referral. Reflux occurs when stomach contents move back into the oesophagus and can cause heartburn and other symptoms.

Long-term reflux is one risk factor for Barrett’s oesophagus. Others include older age, smoking, being overweight and a family history of Barrett’s or oesophageal cancer. Having a risk factor does not by itself mean a person needs a capsule-sponge test; the draft describes a specific patient group, rather than a test for everyone with heartburn.

People whose symptoms require an urgent suspected-cancer referral are outside that proposed detection group. A capsule-sponge test is not a substitute for urgent assessment where it is needed.

Barrett’s oesophagus raises the risk of cancer developing in the food pipe, but most people with the condition do not develop cancer. Monitoring looks for further changes in the cells so that problems can be investigated and, where appropriate, treated.

How the sponge works

A patient swallows a small capsule attached to a thread. The capsule dissolves in the stomach and releases a sponge, which takes about seven minutes to expand. A trained healthcare professional then pulls it back up by the thread. As it passes through the oesophagus, it collects cells from the lining for laboratory analysis.

The procedure does not require sedation and can be carried out in primary care or a community diagnostic centre. Endoscopy instead uses a flexible tube with a camera to examine the upper digestive tract. A patient may be offered a throat-numbing spray or sedation to make a gastroscopy more comfortable.

The sponge test does not provide a final diagnosis on its own. People with a positive result are referred for an endoscopy to investigate and confirm the finding. Endoscopy can also take tissue samples and remains important in the pathway.

Some people experience discomfort when the sponge is removed, or a sore or irritated throat afterwards. Serious adverse events are rare. Services also need arrangements for urgent endoscopy if a sponge cannot be retrieved normally, for example if the thread breaks.

Benefits and limits

Wider use could reduce demand for some endoscopies and offer a less invasive choice closer to home. The committee considered evidence that many patients prefer the sponge test, although individual preferences and suitability will differ.

Neither the sponge test nor endoscopy finds every case. In studies considered for detecting Barrett’s oesophagus, the proportion of cases identified by capsule-sponge testing ranged from 73 to 80 per cent. The studies had different designs, and there was uncertainty around the accuracy estimates. A negative result therefore does not guarantee that a condition has been ruled out; people need advice about when to seek further help if symptoms change or persist.

For people already diagnosed with Barrett’s oesophagus, existing guidance includes endoscopic surveillance, with the interval depending on the length and characteristics of the affected area and individual risk. The draft would add capsule-sponge testing as an option within that pathway, not abolish follow-up or make every endoscopy unnecessary.

What happens next

Comments on the draft close at 5pm on 7 December. The committee is due to meet again on 16 December to consider responses, and final guidance is expected in February 2027, subject to the remaining stages of the process.

If the recommendations are confirmed, the draft envisages funding in England within 90 days of final publication for the specified groups when a capsule-sponge test is the most suitable option. Putting the pathway into practice would also require trained staff and laboratory arrangements. Until final guidance is issued, the recommendations can still change.

Feature image by Ogulcan Aksoy from AdobeStock

Pin It on Pinterest